This page collects WhisperX intelligence signals tagged #Drug Approval. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
The FDA has approved Denali Therapeutics' new drug for Hunter syndrome, a significant decision that arrives as the agency tightens its standards for rare disease treatments. This approval for the drug, named Avlayah, stands in stark contrast to the agency's recent rejection of a competing gene therapy from Regenxbio, w...
The FDA's accelerated approval of Denali Therapeutics' Hunter syndrome drug marks a notable pivot, offering a rare disease win following a recent series of tougher regulatory decisions. This move provides immediate hope for patients and signals a potentially more receptive pathway for certain high-need therapies, contr...
The FDA has delivered a second, decisive rejection to Replimune Group's experimental treatment for advanced melanoma, solidifying the therapy's status as a flashpoint in a high-stakes debate over regulatory standards. This engineered virus, designed to activate the immune system against skin cancer, was initially turne...
In a notable regulatory decision, the FDA has approved Travere Therapeutics' drug for the rare kidney disease focal segmental glomerulosclerosis (FSGS), even though the treatment did not demonstrate an improvement in kidney function in its pivotal trial. This approval, for the drug sparsentan (branded as Filspari), mar...
A major scientific review has reignited a fierce and long-running battle over the fundamental premise of Alzheimer's disease treatment. A sweeping Cochrane review is fueling fresh, intense debate over the effectiveness of amyloid-targeting drugs, the dominant class of therapies for the condition. This development strik...
The FDA is revisiting a rare cancer treatment it previously rejected just months ago, according to sources familiar with the matter, raising questions about the regulatory process and broader concerns about political pressure on drug reviews. The reconsideration comes as FDA leadership faces mounting accusations of po...